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  Evidence-based answer
No, the risks seem to be minimal. 
Arthralgias and myalgias have been 
observed clinically in children and 
adolescents exposed to fl uoroquinolones, 
but they’re transient, disappear when the 
drug is discontinued, and appear to be no 
more prevalent than with other antibiotics 
(strength of recommendation [SOR]: B, 
1 structured review and 2 prospective 
cohort studies). No apparent long-term 
risk of developmental skeletal growth 
delay is associated with fl uoroquinolone 
exposure (SOR: B, 1 prospective controlled 
study). Fluoroquinolone use in children 
isn’t associated with tendonopathy (SOR: 
B, 1 prospective controlled study), but it 
probably carries a very low risk of tendon 
rupture (SOR: C, extrapolation from a 
national passive postmarketing monitoring 
system study predominantly in adults). 
Clinical commentary
Be judicious
Just because you can do something 
doesn’t mean you should. It’s reassuring 
that quinolones can be given to pediatric 
patients if necessary inasmuch as the 
drugs don’t appear to cause long-term 
skeletal side effects, and the infrequent 
arthralgias and myalgias they produce 
seem to be transient and benign. However, 
in an era of increasing microbial drug 
resistance and escalating pharmaceutical 
costs, we should strive for rational 
prescribing and reserve quinolones for 
patients who truly need them.
Stefan M. Groetsch, MD 
Naval Branch Health Clinic, Atsugi, Japan
❚ Evidence summary
Few short-term joint complaints, 
no long-term skeletal harm
A 1997 database review compiled reports 
of skeletally immature patients ranging 
in age from 4 days to 26 years who were 
exposed to quinolones.1 Thirty-one re-
ports met search term criteria, for a total 
of 7045 patients. No incidences of qui-
nolone-associated arthralgia were docu-
mented in 30 reports (>5000 patients). 
The review didn’t report the incidence of 
tendonopathy. One report of 1795 pedi-
atric patients documented a small inci-
dence of arthralgias (~1.5%), which was 
considered to be reversible and no more 
than expected for a comparable quino-
lone-naïve population. 
Follow-up data on safety and ad-
verse fi ndings, from as long as 12 years 
after treatment, were reported for 530 
(28%) of the 7045 patients. Changes 
in skeletal growth were evaluated using 
various diagnostic techniques. Clini-
cal observation was the most common 
method of assessment (N=357), how-
ever. The follow-up data revealed no ar-
thropathy or abnormal skeletal growth 
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(rate=0%; estimated 95% confi dence 
interval [CI]=0%-0.04%).
A prospective study published in 2006 
monitored joint toxicities (swelling, ten-
derness, or restricted movement) during 
acute treatment with ciprofl oxacin as well 
as skeletal growth at follow-up based on 
physical examination.2 Preterm neonates 
with septicemia were treated with either 
ciprofl oxacin (n=48) or other antibiotics 
(n=66). Forty infants in the ciprofl oxacin 
group completed an average of 28 months 
of follow-up. No complaints or physical 
fi ndings of osteoarticular joint abnormali-
ties or skeletal growth delay were noted in 
either group during acute treatment or at 
follow-up. The incidence of tendonopathy 
was not reported.
Arthralgias, myalgias are transient
A large multicenter, prospective, non-
blinded cohort study evaluated adverse 
effects in children receiving fl uoroquino-
lones versus other antibiotics.3 Duration 
of fl uoroquinolone use was 1 to 23 days. 
Arthralgias or myalgias, which were 
only evaluated clinically, occurred more 
often in children receiving fl uoroquino-
lones—10 of 276 children (3.6%) vs 1 
of 249 (0.3%), respectively (odds ratio 
[OR]=9.3; 95% CI, 1.2-195; P=.02). All 
events occurred within the fi rst 2 weeks 
of fl uoroquinolone treatment and re-
solved within 20 days. No tendonopa-
thies were reported.
Tendon rupture is rare, 
especially in children
A 1996 study reported the incidence of 
tendon disorders related to fl uoroquino-
lones using drug surveillance data from 
the general population. The average age 
of the patients was 55 years.4 
The author estimated the risk of ten-
don rupture associated with norfl oxacin 
or ofl oxacin to be 1 case per 23,130 days 
of treatment and only 1 case per 779,600 
days of ciprofl oxacin treatment. The esti-
mated risk would likely be even lower in 
children, the author noted, because the 
risk of tendon rupture increases with age. 
Recommendations 
Ciprofl oxacin is the only fl uoroquino-
lone approved by the US Food and Drug 
Administration for pediatric indications. 
The FDA recently ordered the addition 
of a Boxed Warning to fl uoroquinolones 
regarding the increased risk of tendonitis 
and tendon rupture. The FDA made no 
comments specifi cally about children or 
adolescents, and stated that the risks are 
increased in people older than 60. 
The American Academy of Pedi-
atrics recommends limiting fl uoroqui-
nolone use to children with infections 
caused by multidrug-resistant pathogens 
or children for whom parenteral therapy 
is not feasible and no other effective oral 
medication is available.5 
The Agency for Healthcare Research 
and Quality (AHRQ) recommends fl uoro-
quinolones as fi rst-line treatment for chil-
dren with uncomplicated gonorrhea who 
weigh more than 45 kg,6 and second-line 
therapy for children with bacterial menin-
gitis,7 nongonococcal urethritis, chlamyd-
ia,6 or pelvic infl ammatory disease.8 ■ 
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